5-HT7 Antagonist Reverses Cognitive Deficit in Rats
Author Information
Author(s): Bonaventure Pascal, Aluisio Leah, Shoblock James, Jamin D. Fraser, Ian C. Lord, Brian Lovenberg, Timothy W. Galici, Ruggero Johnson
Primary Institution: Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
Hypothesis
Can the selective 5-HT7 antagonist SB-269970 improve working memory deficits in rats by modulating cortical glutamate and dopamine neurotransmission?
Conclusion
The study found that the 5-HT7 receptor antagonist SB-269970 reversed cognitive deficits induced by MK-801 but not those induced by scopolamine.
Supporting Evidence
- SB-269970 significantly reversed MK-801-induced cognitive deficits in the delayed non-matching to position task.
- SB-269970 did not affect dopamine levels but normalized glutamate levels in the prefrontal cortex.
- The pharmacokinetic study showed that SB-269970 did not alter the plasma and brain concentrations of MK-801.
Takeaway
Researchers tested a drug on rats to see if it could help them remember things better, and it worked for some types of memory problems but not others.
Methodology
The effects of SB-269970 were evaluated in a delayed non-matching to position task and its impact on glutamate and dopamine levels was measured using biosensor technology and microdialysis.
Potential Biases
Potential conflicts of interest due to funding from Johnson & Johnson Pharmaceutical Research and Development.
Limitations
The study's findings may not be generalizable to all types of cognitive deficits or other species.
Participant Demographics
Male Sprague-Dawley rats, weighing 250-350 grams.
Statistical Information
P-Value
p<0.00005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website